On September 3, 2019 argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, reported that Tim Van Hauwermeiren, Chief Executive Officer, will present at the Morgan Stanley 17th Annual Global Healthcare Conference on Monday, September 9, 2019 at 10:30 am ET in New York (Press release, argenx, SEP 3, 2019, View Source [SID1234539204]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The live webcast may be accessed on the homepage of the argenx website at www.argenx.com. Shortly after the presentation, a replay of the webcast will be available for 90 days on the argenx website.

On September 3, 2019 Luminex Corporation (NASDAQ: LMNX) reported that Homi Shamir, President and Chief Executive Officer, will participate in an analyst-led fireside chat at the Morgan Stanley 17th Annual Global Healthcare Conference to be held September 9-11, 2019, in New York, NY (Press release, Luminex, SEP 3, 2019, View Source [SID1234539221]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The fireside chat will begin at 2:05 p.m. Eastern Time on Tuesday, September 10, 2019.

The presentation will be webcast live and may be accessed at Luminex Corporation’s website at www.luminexcorp.com. Simply log on to the web at the address above, go to the Company section and access the Investor Relations link. The presentation will be archived for six months on the website using the ‘replay’ link.

On September 3, 2019 Physicians’ Education Resource (PER), a worldwide leading resource for continuing medical education, reported that it will present the 4th Annual International Congress on Immunotherapies in Cancer: Focus on Practice-Changing Application on Saturday, Dec. 14, at the InterContinental New York Times Square in New York City (Press release, Physicians’ Education Resource, SEP 3, 2019, View Source [SID1234539237]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The program will be co-chaired by Naiyer A. Rizvi, M.D., professor of medicine; director, thoracic oncology; co-director, cancer immunotherapy program; and the Price Family Professor of Medicine, Columbia University Medical Center; and Mario Sznol, M.D., professor of medicine; leader, melanoma disease related translational team; co-director, YALE SPORE in skin cancer; and co-director, cancer immunology program, Yale Cancer Center.

"We look forward to this year’s International Congress on Immunotherapies in Cancer," said Phil Talamo, president of PER. "This annual educational program brings together oncologists, nurses and pharmacists to highlight the fundamental principles and pivotal advancements within the past year surrounding the evolving role of immunotherapies and their role in cancer treatment."

The 4th Annual International Congress on Immunotherapies in Cancer is a one-day interactive program that will provide attendees with a comprehensive review of the key data sets that are most relevant to the application of these novel strategies for the clinician who manages some of the most difficult-to-treat forms of cancer. Top experts will lead discussions that focus on the practical application of recent clinical trial results that have shaped current and evolving clinical management, evolving biomarker information, the latest basic science findings and the most highly anticipated clinical trials in the field. As an exciting, fast-paced congress, this meeting will provide a multimodule, curriculum-based program that focuses exclusively on immunotherapies and their application to the management of cancer.

On September 3, 2019 Kitov Pharma Ltd. ("Kitov") (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, reported that Isaac Israel, CEO, and Gil Efron, Deputy CEO and CFO, will participate in the H.C. Wainwright 21st Annual Healthcare Conference that is being held in New York on September 8-10, 2019 (Press release, Kitov Pharmaceuticals , SEP 3, 2019, View Source [SID1234539254]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Mr. Israel will provide an overview of Kitov’s business strategy and pipeline during the live presentation. They will also participate in one-on-one meetings with investors who are registered to attend the conference.

Details of presentation are as follows:

H.C. Wainwright Annual Healthcare Conference

Presentation Date: September 10, 2019

Presentation Time: 12:05 p.m. – 12:30 p.m. ET

Location: Lotte New York Palace Hotel, New York, USA

The updated Kitov corporate presentation will be made available on the "Investor Relations" section on the Kitov website at View Source

On September 3, 2019 BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) reported that the company will present at the H.C. Wainwright Global Investment Conference in New York on Monday, September 9, 2019 at 9:10 a.m. ET (Press release, BioCryst Pharmaceuticals, SEP 3, 2019, View Source [SID1234539186]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Links to a live audio webcast and replay of the presentation may be accessed in the Investors section of BioCryst’s website at http://www.biocryst.com.